Study to Evaluate the Efficacy and Safety of Oral RP7214, a DHODH Inhibitor, in Patients With Symptomatic Mild COVID-19 Infection.
Clinical trial NCT05007236 · COMPLETED
Trial details
- NCT number
- NCT05007236
- Sponsor
- Rhizen Pharmaceuticals SA
- Status
- COMPLETED
- Phase
- Phase 2
- Study type
- INTERVENTIONAL
- Start date
- 2021-09-20
- Primary completion
- 2022-03-25
- Enrollment
- 163
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.